Cyclopharm Stock

Cyclopharm EBIT

The EBIT of Cyclopharm (CYC.AX) as of Aug 13, 2026 is -14.52 M AUD. In the previous year, EBIT was -8.60 M AUD — a change of 68.82% (lower).

EBIT

-14.52 MAUD

YoY

68.82%

Last updated:

In 2026, Cyclopharm's EBIT was -14.52 M AUD, a 68.82% increase from the -8.60 M AUD EBIT recorded in the previous year.

The Cyclopharm EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M AUD)
Date
EBIT (M AUD)
Jan 1, 2021
-4.52 base
Jan 1, 2022
-5.89 base
Jan 1, 2023
-8.60 base
Jan 1, 2024
-14.52 base
Jan 1, 2025 (e)
-12.66 base
Jan 1, 2026 (e)
-14.34 base
Jan 1, 2027 (e)
-18.10 base
Jan 1, 2028 (e)
-21.67 base
YEAREBIT (M AUD)
2028 est -21.67
2027 est -18.10
2026 est -14.34
2025 est -12.66
2024 -14.52
2023 -8.60
2022 -5.89
2021 -4.52
2020 -5.48
2019 -3.31
2018 -0.17
2017 0.73
2016 1.44
2015 2.01
2014 0.63
2013 -0.41
2012 -0.43
2011 -0.05
2010 1.59
2009 2.70
2008 2.15
2007 1.61
2006 2.63
2005 2.72
Access this data via the Eulerpool API

Cyclopharm Revenue

Cyclopharm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
17.85 M AUD
-4.52 M AUD
-5.04 M AUD
Jan 1, 2022
24.96 M AUD
-5.89 M AUD
-6.61 M AUD
Jan 1, 2023
27.77 M AUD
-8.60 M AUD
-4.70 M AUD
Jan 1, 2024
27.57 M AUD
-14.52 M AUD
-13.20 M AUD
Jan 1, 2025 (e)
32.30 M AUD
-12.66 M AUD
-8.85 M AUD
Jan 1, 2026 (e)
36.60 M AUD
-14.34 M AUD
-15.44 M AUD
Jan 1, 2027 (e)
46.20 M AUD
-18.10 M AUD
-7.20 M AUD
Jan 1, 2028 (e)
55.30 M AUD
-21.67 M AUD
-2.88 M AUD

Cyclopharm Margins

Cyclopharm stock margins

The Cyclopharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cyclopharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cyclopharm.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
71.75 %
-25.30 %
-28.24 %
Jan 1, 2022
70.20 %
-23.59 %
-26.48 %
Jan 1, 2023
63.06 %
-30.97 %
-16.93 %
Jan 1, 2024
65.04 %
-52.65 %
-47.86 %
Jan 1, 2025 (e)
65.04 %
-39.18 %
-27.40 %
Jan 1, 2026 (e)
65.04 %
-39.18 %
-42.17 %
Jan 1, 2027 (e)
65.04 %
-39.18 %
-15.59 %
Jan 1, 2028 (e)
65.04 %
-39.18 %
-5.21 %

Cyclopharm Stock analysis

What does Cyclopharm do? Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Cyclopharm's EBIT

Cyclopharm's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cyclopharm's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cyclopharm's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cyclopharm’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cyclopharm stock

EBIT of Cyclopharm is -14.52 M AUD in 2026.

EBIT of Cyclopharm changed from -8.60 M AUD to -14.52 M AUD, representing a 68.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Cyclopharm since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Cyclopharm historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Cyclopharm

All Key Metrics — Cyclopharm